Search Results
Found 74 results for "AstraZeneca" across articles, medicines, trials, companies and the glossary
MedicinesAll 66 →
Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspensionFormoterol fumarate dihydrate, GLYCOPYRRONIUM · AstraZeneca AB
Bricanyl 500 micrograms/ml solution for injection or infusionTerbutaline sulfate · AstraZeneca AB
Bricanyl Turbohaler 500 micrograms per metered dose, inhalation powderTerbutaline sulfate · AstraZeneca AB
Brilique 60 mg film-coated tabletsTicagrelor · AstraZeneca AB
Brilique 90 mg film-coated tabletsTicagrelor · AstraZeneca AB
Brilique 90 mg orodispersible tabletsTicagrelor · AstraZeneca AB
Industry
Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines
Global equity markets open August 2026 on a historic high as rumored $400B AstraZeneca-BMS merger talks and Curium's $8B Lantheus acquisition spark a massive biopharmaceutical consolidation wave.
Industry
UK Pharma CV Guide 2026: MHRA Standards, Golden Triangle Hubs & Free ATS CV Builder
Complete 2026 guide to writing an ATS-compliant pharmaceutical CV in the UK. Features MHRA & ABPI standards, UK 2-page CV conventions, Golden Triangle recruitment benchmarks, and free ATS CV Studio tools.
Pharmaceutical
The Irish Distortion: How Multinational Pharma Giants Warped the EU’s Economic Landscape
Ireland’s status as a corporate hub for global pharmaceutical multinationals has created a unique statistical paradox-masking true economic health and dragging the EU’s GDP into negative territory in the first quarter of 2026. We examine the tax structures, tariff-hedging inventory builds, and supply chain strategies driving this anomaly.
Clinical Trials
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.
Biotechnology
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.